Revista de Oncología Integrativa

A Rare Case OF HER 2 Amplified and MET Mutated Metastatic Gastric Cancer with Clinical Benefit to MET Inhibition: A Case Report

Abstract

Dr. Joydeep Ghosh

The treatment of metastatic stomach cancer has evolved over the last few years. Presently, the most common chemotherapy regimen comprises of Fluorouracil and platinum-based combinations. In the case of HER 2 positive disease, the treatment involves a combination of chemotherapy with trastuzumab. However, there have been cases of resistance to the above combination. Multiple underlying molecular mechanisms have been postulated for the resistance. One of the commonest pathways is CMET mutation. However, the presence of C MET and HER 2 is very rare. Here, we present such a rare case of metastatic stomach cancer who had abnormalities in both the pathways leading to resistance to Trastuzumab.